

PCT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants Billot, et al.

Serial No. 10/511,737

Filed: October 18, 2004

For: EP4 RECEPTOR AGONIST, COMPOSITIONS AND
METHODS THEREOFArt Unit: To be assignedExaminer: to be assigned

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97**

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Ry. Aiken Date 3-16-05

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

By: Sylvia A. Ayler

Attorney For Applicant(s)

Reg. No. 36,436

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-4909

Date: March 16, 2005

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

1

of

4

COMPLETE IF KNOWN

Application Number	10/511,737
Filing Date	October 18, 2004
First Named Inventor	Billot, et al.
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	MCO59YP

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		4,386,098		Woltersdorf, Jr.	05/31/1983
		4,416,890		Woltersdorf, Jr.	11/22/1983
		4,426,388		Woltersdorf, Jr.	01/17/1984
		4,668,697		Shepard, et al.	05/26/1987
		4,863,922		Baldwin, et al.	09/05/1989
		4,797,413		Baldwin, et al.	01/10/1989
		5,378,703		Dean, et al.	01/03/1995
		5,240,923		Dean, et al.	08/31/1993
		5,153,192		Dean, et al.	10/06/1992
		4,883,819		Bito, et al.	11/28/1989
		4,824,857		Goh, et al.	04/25/1989
		5,001,153		Ueno, et al.	03/19/1991
		4,599,353		Bito, et al.	07/08/1986
		6,043,275		Maruyama, et al.	03/28/2000
		5,698,598		Woodward, et al.	05/01/1998
		5,462,968		Woodward, et al.	10/31/1995
		6,344,477 B1		Sharif, et al.	02/05/2002
		5,889,052		Klimko, et al.	03/30/1999
		5,296,504		Stjerschantz, et al.	03/22/1994
		5,422,368		Stjerschantz, et al.	06/06/1995

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
		PCT	WO 00/38667 A3		Alcon Laboratories, Inc.	07/06/2000
		PCT	WO 99/32441		Alcon Laboratories, Inc.	07/01/1999
		PCT	WO 99/02165		Pharmacia & Upjohn AB	01/21/1999
		PCT	WO 00/38663		Alcon Laboratories, Inc.	07/06/2000
		PCT	WO01/46140 A1		Pfizer Products Inc.	06/28/2001
		EP	0 855 389 A2		Ono Pharmaceutical Co., Ltd.	01/26/1998
		JP	2000-1472			
		PCT	WO 00/38690		Alcon Laboratories, Inc.	07/06/2000
		PCT	WO 02/24647 A1		Ono Pharmaceutical Co. Ltd.	03/28/2002
		PCT	WO 02/42268 A2		Pfizer Products Inc.	05/30/2002

Examiner
Signature

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

STATEMENT BY APPLICANT

(use ~~as~~ many sheets as necessary)

2

of

4

COMPLETE IF KNOWN**Application Number**

10/511,737

Filing Date

October 18, 2004

First Named Inventor

Robert Young, et al.

Group Art Unit

To be assigned

Examiner Name

To be assigned

Attorney Docket Number

MCO59 YP

U.S. PATENT DOCUMENTS

[illegible]


FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
		EP	0 561 073 A1		R. Tech Ueno, Ltd.	08/24/1992
		EP	1 114816 A1		Ono Pharmaceutical Co., Ltd.	09/10/1999
		PCT	WO 01/72268 A1		Toray Industries Inc.	12/04/2001
		PCT	WO 02/077168 A2		Merck & Co., Inc.	10/03/2002
		PCT	WO 02/060863 A1		Merck & Co., Inc.	08/08/2002
		PCT	WO 94/13275		Massachusetts Eye & Ear Infirmary	06/23/1994
			Belgium Patent 672,205		Procter & Gamble Company	11/10/1965

Examiner
SignatureDate
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)			COMPLETE IF KNOWN		
			Application Number	10/511,737	
			Filing Date	October 18, 2004	
			First Named Inventor	Billot, et al.	
			Group Art Unit	To be assigned	
			Examiner Name	To be assigned	
Sheet	3	of	4	Attorney Docket Number	MCO59YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	AA	Ichikawa, et al., J. Lipid Mediators Cell signalling, "Molecular aspects of the structures and functions of the prostaglandin E receptors", (1996), Vol. 14, pp. 83-87
	AB	Flach, et al., Journal of Ocular Pharmacology, "Topical Prostaglandin E2 Effects on Normal Human Intraocular Pressure", (1988), Vol. 4, No. 1, pp. 13-18
	AC	Woodward, et al., Journal of Ocular Pharmacology and Therapeutics, "Molecular Characterization and Ocular Hypotensive Properties of the Prostanoid EP2 Receptor, (1995), Vol. 11, No. 3, pp. 447-454
	AD	Woodward, et al., Journal of Lipid Mediators, "Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand binding studies", (1993), Vol. 6, pp. 545-553
	AE	Waterbury, et al., Investigative Ophthalmology & Visual Science, "EP3 But Not EP2, FP or TP Prostanoid-Receptor Stimulation May Reduce Intraocular Pressure", (1990), Vol. 31, No. 12, pp. 2560-2567
	AF	Gipson, et al., Progress in Retinal and Eye Research, "Mucin Genes Expressed by the Ocular Surface Epithelium", (1997), Vol. 16, No. 1, pp. 81-98
	AG	Dartt, et al., Current Eye Research, "Localization of nerves adjacent to goblet cells in rat conjunctiva", (1995), Vol. 14, pp. 993-1000
	AH	Robert A. Schumer, Arch. Ophthalmol, "The Nerve of Glaucoma", (1994), Vol. 112, pp. 37-44
	AI	Dandona, et al., Invest. Ophthalmol. Vis. Sci., "Selective Effects of Experimental Glaucoma on Axonal Transport by Retinal anglion Cells to the Dorsal Lateral Geniculate Nucleus", (1991), Vol. 32, No. 5, pp. 1593-1599
	AJ	Quimby, et al., J. Org. Chem., "Tetrasodium Carbonyldiphosphonate, Synthesis, Reactions, and Spectral Properties, (1967), Vol. 32, pp. 4111
	AK	Abramovitz, et al., Biochimica et Biophysica Acta 1483(2) (2000), "The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs, pp 285-293
	AL	Elliott M. Ross, Goodman & Gilman's The Pharmacological Basis of Therapeutics, "PHARMACODYNAMICS Mechanisms of Drug Action and the Relationship Between Drug Concentration and Effect", Ninth Edition, Chapter 2, (1996)
	AM	Lemp, et al., The CLAO Journal, Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes", (1995), Vol. 21, No. 4, pp. 221-231
	AN	Ikeda, et al., J. Bone Miner Res. 10, In situ localization of three subtypes (EP1, EP3 and EP4) of prostaglandin E receptors in embryonic and newborn mice", (sup 1):S172
	AO	Rodan, et al., Endocrinology, (1987), Vol. 121:No. 6 "Growth Stimulation of Rat Calvaria Osteoblastic Cells by Acidic Fibroblast Growth Factor, pp. 1919-1923

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/511,737
---------------------------	------------

Filing Date	October 18, 2004
--------------------	------------------

First Named Inventor	Billot, et al.
-----------------------------	----------------

Group Art Unit	To be assigned
----------------	----------------

Examiner Name	To be assigned
---------------	----------------

Attorney Docket Number MCO59YP

NON PATENT LITERATURE DOCUMENTS

Examiner
Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder). Merck & Co., Inc.. 09/05/2003